The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous ophthalmic pharmaceutical composition of the invention includes sucrose as a sugar, a citrate buffer, polysorbate 80 as a surfactant, wherein the pH of the composition is about 6.3 to about 7.3, and wherein the maximum number of particles ≥ 10 μm in said composition is 50 per mL.
